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Background/aim: Transcatheter aortic valve implantation (TAVI) has emerged as a new therapy in aortic stenosis patients with high
operative risk. Advances in experiences have shifted the choice of anesthesia from general to local anesthesia and sedation for these
patients. We compared our anesthetic experiences in our institute in a period of 2.5 years.
Materials and methods: A total of 151 (86 females, 65 males, mean age 76 years) symptomatic aortic stenosis patients undergoing
transfemoral TAVI under general anesthesia (GA) (n = 79) and local anesthesia and sedation (LAS) (n = 72) were evaluated retrospectively
in regards to anesthetic issues.
Results: The mean European System for Cardiac Operative Risk Evaluation (EuroSCORE) values of patients in the GA and LAS groups
were 17 and 12, respectively. The anesthesia duration was significantly shorter in the LAS group (P < 0.001) and 16.7% of the patients in
the LAS group were switched to general anesthesia. Length of stay in the intensive care unit was similar in the two groups.
Conclusion: TAVI, applied in high-risk populations, has many challenges for anesthesiologists. With technological advances, it is
possible to perform these procedures under sedation with variable advantages. Thus, future studies in regard to anesthesia are required
for the success of the procedure and patient safety.
Key words: Transcatheter aortic valve implantation, aortic stenosis, general anesthesia, local anesthesia, sedation

1. Introduction
Transcatheter aortic valve implantation (TAVI) is an
alternative technique to surgical aortic valve replacement
in inoperable/high-risk patients with aortic stenosis
(1). Anesthetic techniques in these interventions are
quite important due to significant challenges about their
management in a population of old and high-risk patients
(2). However, there is still a lack of consensus with respect
to the best anesthesiological approach for these patients.
Taking into account that these patients will have more
advantages from a noninvasive surgical approach, it is also
suggested that they will benefit from less invasive anesthesia
techniques (3–5). However, general anesthesia (GA) provides
multiple advantages by maintaining patient immobility, use
of transesophageal echocardiography (TEE), and facilitating
the management of procedural complications (6). Local
anesthesia and sedation (LAS) has recently been described
as an alternative valid technique that probably brings the
necessity of increased experience of the team (7).
We herein investigate the anesthesia-linked outcomes
of patients undergoing TAVI at our institution over a
period of 2.5 years.
* Correspondence: elvinku@yahoo.com
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2. Materials and methods
We investigated the data of patients retrospectively in
regards to anesthetic issues. Between July 2011 and
January 2014, 151 TAVI procedures were performed via a
transaxillary (n = 3) or transfemoral (n = 148) approach at
our institution.
Routinely, following the evaluation of the individual
patient on the basis of international recommendations by
the cardiologist, cardiac surgeon, and anesthesiologist, a
decision for not only high risk of conventional surgery but
also the suitability of TAVI is made in our clinics (8–12).
Preoperatively, in addition to clinical evaluation, all patients
are screened by transthoracic echocardiography (TTE),
coronary angiography, iliofemoral contrast angiography,
and computed tomography. Thus, the anesthesiologist
determines the anesthetic management to be offered.
For this report, the patients were followed up in the
aspect of clinical data, transthoracic echocardiographic
results, parameters related to the procedure, and intensive
care unit and hospital stay lengths until hospital discharge.
Afterwards, information on survival in the following
30 days was obtained by telephoning the patient. We
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performed the procedure in the cardiac catheterization
laboratory (CCL), which has sterility precautions
similar to those the operating room, with mobile C-arm
fluoroscopy. A retrograde transfemoral arterial valve
implantation was initially planned for the patients. For
those patients who were not suited for a transfemoral
approach, subclavian access was performed. The
CoreValve (Medtronic CV, Luxembourg) or the Edwards
Sapien (Edwards Lifesciences, USA) bioprostheses were
implanted. Standard technical applications of the TAVI
procedure were applied as have been previously described
(13). Routine anesthetic preprocedural evaluation
focused on cardiovascular parameters, airway control,
and other systemic dysfunctions. Before the procedure,
oral acetylsalicylic acid (100 mg), clopidogrel (300 mg),
and IV antibiotic were administered to all patients. No
premedication was given.
In the operating room, a heating blanket was
placed beneath the patient to prevent hypothermia and
nasopharyngeal temperature was measured during the
procedure. After inserting an IV catheter into a large
arm vein, we applied a 5-lead electrocardiogram, invasive
arterial blood pressure measurement, pulse oximetry, and
central venous pressure monitorization. Pulmonary artery
catheterization was not performed in any of the patients.
At the beginning of the procedure, we administered
heparin (5000 IU, IV) to achieve an activated clotting time
(ACT) of more than 250 s. Local anesthetic infiltration
consisting of 10–20 mL of 1% lidocaine was performed in
each groin. The anesthesiologist decided to perform either
GA or LAS, according to the patient’s health status. For
those undergoing GA, either sodium thiopental (3–5 mg
kg–1), etomidate (3 mg kg–1), or propofol (1–2 mg kg–1) was
used for anesthesia induction. Rocuronium (0.6 mg kg–1)
was used for muscular relaxation. All patients were orally
intubated and mechanically ventilated with a tidal volume
of 4–6 mL kg–1 and a respiratory rate of 12–16 breaths
min–1. End-tidal CO2 concentrations of 30–35 mmHg were
considered as adequate. Then the TEE probe was inserted.
For maintenance of anesthesia, the anesthesiologists
used either sevoflurane (0.8%–1.1% minimum alveolar
concentration) in an oxygen/air mixture at FiO2 of 50%
combined with a remifentanil infusion (0.02–2 µg kg–1
min–1) or a propofol/remifentanil infusion (3–5 mg kg–1
h–1 / 0.02–2 µg kg–1 min–1) (total intravenous anesthesia
technique, TIVA). Due to the difficulty in keeping the
hemodynamic stability in elderly patients with reduced
cardiac output by TIVA, only 5 suitable patients had
been reported to be applied TIVA (6.3%). In the rest of
the patients, inhalational anesthesia with sevoflurane
in combination with remifentanil infusion was chosen.
Remifentanil infusion provided earlier recovery with
a short-lasting muscle relaxant (rocuronium) in these

patients. At the end of the procedure, the patients’
extubation was decided by the anesthesiologist following
the procedure.
Those patients undergoing LAS first had IV midazolam
at 0.05 mg kg–1 and fentanyl at 1 µg kg–1. Supplemental oxygen
by face mask (FiO2 0.5) was provided during the procedure.
The aim was to evaluate the patient’s neurological status;
thus, we paid attention to the patient being consciously
or deeply sedated, according to the guidelines established
by the American Society of Anesthesiologists (ASA)
(14). The patients were sedated such that they responded
purposefully to verbal commands. They were asked to
respond after repeated verbal or painful stimulation if
the sedation level was deepened. If the sedation level was
observed to be insufficient, additional midazolam (1–3
mg IV bolus) or remifentanil infusion (0.025–0.2 µg kg–1
min–1) or propofol infusion (2–5 mg kg–1 h–1) was applied.
The patients had their ACT controls and arterial blood
gas controls routinely during the procedure (for ACT once
at the beginning and once at the end of the procedure,
as well as one control after heparin application). Arterial
blood gas analysis was also performed once at the
beginning and at the end of the procedure. During
the follow-up, the end-tidal CO2 concentrations and
respiratory rates were checked every 5 min. For those
under LAS proper breathing was monitored by observing
the rate and depth of chest and abdominal movements
and pattern of respiration. Oxygen saturation levels under
90%, respiratory rate <6/min, and apnea >20 s or airway
obstruction were treated by the stopping of all sedative
drugs and assisted ventilation by facial mask until an
adequate respiratory drive was reached. Conversion to
GA was performed if the patient tolerated the procedure
poorly or in case of complications.
All through these periods, the mean arterial pressure
was aimed to be kept above 65 mmHg during the procedure.
To achieve this goal, hypovolemia (initial transthoracic
echocardiography findings and central venous pressure
<8 mmHg) was corrected by volume expansion initially
(500 mL colloid infusion). When preload and contractility
were evaluated as optimal (by TEE or hemodynamic
parameters), bolus ephedrine (5 mg) or epinephrine (5 µg)
and/or norepinephrine (0.03–0.06 µg kg–1 min–1) infusions
were used to correct arterial hypotension (systolic arterial
pressure <80 mmHg). Nevertheless, the mean arterial
pressure was increased above 75 mmHg to prevent
deterioration in hemodynamic parameters. Two external
defibrillator pads were attached. Under fluoroscopic
guidance, ventricular pacing was performed at a rate of
180 beats min–1 with a decrease in systolic arterial pressure
to <50 mmHg. The ventricular outflow was minimized
and balloon dilatation of the stenotic valve was performed.
TEE (in intubated patients) was used to confirm proper
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positioning of the prosthesis and to assess perivalvular
or transvalvular aortic regurgitation at the end of the
procedure. However, TEE was not used in patients under
LAS. This decision was made by the team according to the
cardiologist’s experiences and the patient’s aortic valve. In
patients under LAS, fluoroscopic imaging and aortograms
were reported to be as safe as TEE in providing anatomical
details (15).
The femoral artery was closed percutaneously, except
in cases of difficulties, for which the closure was performed
surgically. Extubation immediately after the procedure in
the CCL has been routinely done in our clinic. However,
the long distance between the intensive care unit (ICU)
and the CCL made some of the anesthesiologists prefer
extubation in the ICU. Patients with hemodynamic
instability, acute complications related to femoral/
subclavian vessel manipulations, or rhythm disturbances
at the end of the procedure were not extubated and were
transferred directly to the ICU. Postoperative analgesia
was provided by 1.0 mg kg–1 IV tramadol every 6 h.
Data analysis was performed by using SPSS 11.5 for
Windows (SPSS Inc., Chicago, IL, USA). Whether the
distributions of metric discrete and continuous variables

were normal or not was determined by Shapiro–Wilk test.
Data are shown as mean ± SD or median (min–max) as
applicable. While the mean differences between groups
were compared by Student’s t-test, the Mann–Whitney
U test was applied for comparisons of the median values.
Nominal data were analyzed by Pearson’s chi-square or
Fisher’s exact test as appropriate. Whether the differences
between pre- and posttreatment measurements regarding
LEVF, peak AV, and peak MV were statistically significant
or not was analyzed by the Wilcoxon signed rank test. P <
0.05 was considered as statistically significant.
3. Results
A total of 151 TAVI patients were evaluated in this study
(86 females, 65 males). While 52% of the patients in this
report received GA, as the early phase of the physician
learning curve progressed, we preferred LAS. The mean
age of the patients was 76 years. Baseline characteristics
and comorbidities of the TAVI population are listed in
Table 1. There were significant differences in comorbidities
of the two anesthesia groups since the patients were not
randomly assigned to any group before the procedure and
the data were studied retrospectively.

Table 1. Demographic data and comorbidities of the TAVI patients.
Parameters

Group GA (n = 79)

Group LAS (n = 72)

P-value

Age

76.3 ± 8.6

77.4 ± 8.7

0.458

25 (31.6%)

40 (55.6%)

Sex
Male

0.003

Female

54 (68.4%)

32 (44.4%)

Height (cm)

157.7 ± 11.1

161.8 ± 8.1

0.029

Weight (kg)

69.3 ± 14.4

71.2 ± 14.4

0.514

BMI

27.2 ± 5.1

27.2 ± 5.4

0.955

AF

21 (26.6%)

16 (22.2%)

0.534

RF

4 (5.1%)

6 (8.3%)

0.520

DM

22 (27.8%)

6 (8.3%)

0.002

PVD

8 (10.1%)

10 (13.9%)

0.476

CAD

46 (58.2%)

45 (62.5%)

0.592

MI

5 (6.3%)

32 (44.4%)

<0.001

PCI

42 (53.2%)

20 (27.8%)

0.002

CABG

8 (10.1%)

20 (27.8%)

0.005

COLD

15 (19.0%)

23 (31.9%)

0.067

CVE

3 (3.8%)

10 (13.9%)

0.027

CVS

4 (5.1%)

4 (5.6%)

1.000

AF: Atrial fibrillation, RF: renal failure, PVD: peripheral vascular disease, CAD: coronary
artery disease, MI: myocardial infarction, PCI: percutaneous coronary intervention,
CABG: coronary artery bypass grafting, COLD: chronic obstructive lung disease, CVE:
cerebrovascular event, CVS: coronary valve surgery.
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All the patients presented a high surgical risk (logistic
EuroSCORE: 17.3 in GA group versus 12 in LAS group).
However, the Society of Thoracic Surgeons (STS) score
between the groups was significantly different (STS score:
17 in GA group and 6.7 in LAS group) (P < 0.001).
A retrograde transfemoral approach was suitable in 148
cases in the series, but in three cases, TAVI was performed
by subclavian artery approach. In 6 of the patients with
the transfemoral approach, the procedure required an
open cut down to the vessels. The Edwards Sapien valve
was implanted in the majority of patients (n = 97), while
the Medtronic CoreValve Revalving System was chosen
in only 54 patients. Procedural and anesthesia-related
outcomes are reported in Table 2. No complications,
such as device migration, prosthesis malpositioning,
obstruction of coronary ostia, or myocardial infarction,
occurred in the patients. The persistent atrioventricular
block resulting after the procedure in 3 patients in GA
group and 5 patients in LAS group was treated with
permanent pacemaker implantation.
In the GA group, 62% of the patients were extubated
in the ICU. Those were the patients with hemodynamic
instability, vascular complications, and rhythm
disturbances at the end of the procedure. Only 6% had
mechanical ventilation periods longer than 48 h. In the
LAS group, 16.7% of the patients failed to go on with this
technique as a consequence of restlessness and a case of
refractory ventricular fibrillation, and thus they had general
anesthesia. The mean length of stay in the ICU in both of
the groups was 3 days. However, mean length of stay in the
hospital was significantly different between the groups (13
days vs. 6 days, P < 0.001). Fifteen patients in the GA and

six patients in the LAS group had vascular complications.
The percentage of survival in the GA and LAS groups
was 91% and 86% respectively after 30 days (P > 0.05).
Both groups had significantly better echocardiographic
results after the procedure (Table 3). Although neither the
patients nor the cardiologist described any complaints, we
did not document their satisfaction states.
4. Discussion
The results of this comparative study show that both GA
and LAS are safe and feasible techniques for noninvasive
transcatheter procedures.
At our institution, we preferred general anesthesia with
tracheal intubation and continuous TEE monitorization
in our first experiences. A balanced anesthesia technique
(sevoflurane combined with remifentanil infusion)
allowed rapid recovery in the elderly patients. Another
protocol with propofol/remifentanil infusion (TIVA) was
also used for maintenance of anesthesia. However, the
hemodynamic stabilization was not easy in these elderly
patients with reduced cardiac output by TIVA technique.
That is why we applied this technique only in 5 suitable
patients (6.3%). All of our patients were transferred to the
ICU at the end of the procedure. The number of patients
extubated in the ICU was more than the ones extubated in
CCL. Nevertheless, like Covello et al. we switched to the
use of local anesthesia and sedation following an assumed
learning curve (16). Interestingly, the STS scores of the
GA group were significantly higher than those of the LAS
group. There are other studies comparing experiences
with anesthesia techniques in patients undergoing TAVI
(13,17–21). Goren et al, reported a rate of 4.6% conversion

Table 2. Procedural and anesthesia-related outcomes.
Parameters

Group GA (n = 79)

Group LAS (n = 72)

P-value

EuroSCORE (logistic)

17.3 (1.0–69.5)

12.0 (1.4–41.1)

0.027

STS score

17.0 (2.4–73.0)

6.7 (1.7–31.0)

<0.001

Anesthesia duration (min)

149.0 ± 48.7

124.7 ± 34.3

<0.001

Procedure duration (min)

109.3 ± 46.6

91.6 ± 34.7

0.010

Permanent pacemaker requirement

3 (3.8%)

5 (6.9%)

0.479

Length of stay in ICU (days)

3 (1–29)

3 (1–13)

0.225

Length of stay in hospital (days)

13 (3–33)

6 (1–25)

<0.001

Postop inotropic agent requirement

8 (10.1%)

7 (9.7%)

0.934

Vascular complication

15 (19%)

6 (8.3%)

0.059

Emergent vascular surgery

8 (10.1%)

5 (8.3%)

0.486

Mortality in first 30 days

7 (8.9%)

10 (13.9%)

0.329
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Table 3. Comparison of echocardiographic parameters between the groups.
Parameters

Before TAVI

After TAVI

P-value

Change (∆)

Group GA

60 (15–70)

65 (20–65)

<0.001

0 (–15 to 30)

Group LAS

60 (10–69)

65 (12–65)

<0.001

0 (–14 to 29)

P-value

0.835

0.693

Group GA

74.5 (37.0–125.0)

19.5 (8.0–34.0)

<0.001

–56.5 (–108 to -28)

Group LAS

83 (54–136)

20 (7–40)

<0.001

–61.5 (–118 to -33)

P-value

0.107

0.676

Group GA

49.5 (24.0–101.0)

9.0 (3.0–17.0)

<0.001

–41 (–90 to –20)

Group LAS

48.5 (29–83)

9 (3–23)

<0.001

–38 (–73 to –20)

P-value

0.497

0.114

LEVF

0.269

Peak AV

0.138

Mean AV

from sedation to GA recently (18). The difference
between that and our findings might be attributable to
the experiences of anesthesiologists in TAVI procedures.
We also collected the data retrospectively. Although the
limits of dosages of sedative agents were exact and known,
every anesthesiologist had his own applications. These
data could have been interpreted more precisely if the total
consumptions of agents had been documented.
In early studies, it was reported that GA with a fasttrack protocol is the most appropriate and safest anesthesia
technique for this approach (5,15,16). Billings et al.
described 29 cases of TAVI, suggesting GA as a mandatory
technique, because of the consequence of the procedure
itself and the necessity of TEE (4). However, TEE could
sometimes be misleading in distinguishing the prosthesis
while crimped on the delivery system and it may interfere
with fluoroscopic imaging, necessitating probe withdrawal
at the time of implantation (22–24). Angiography could
thus be associated with the same clinical and hemodynamic
results (22).
Some authors prefer GA even after an initial
experience with sedation. Gümüş et al. and Yamamoto et
al. preferred local anesthesia and sedation in their practice
after a period of experience with GA (17,25). Yamamoto
et al. failed to show any difference in procedure success;
30-day mortality and the difference in length of stay
in the ICU and hospital was significant in the sedation
group in comparison to the GA group. However, they
suggested the importance of experience for this switch,
since they evaluated the conversion of 6 patients from
local anesthesia and sedation to GA as an early and urgent
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attempt for a change in anesthesia technique (17). In
their experience, Petronia et al. described that patients
in the GA group had higher EuroSCOREs and longer
procedural times. Conversely, length of stay in the hospital
was significantly shorter in their local anesthesia group
(19). The EuroSCOREs of our patients in the GA group
were also higher in our study. Interestingly, STS scores
of the LAS group were found to be significantly higher
in our study. One explanation for this could be more
parameters taking place in the STS scoring system. More
detailed information about these elderly patients could
have included increased disabilities and morbidities, thus
increasing the score. Nevertheless, patients with increased
frailty could have led the anesthesiologists to avoid GA for
this procedure, in our experience. Similarly to Petronia et
al., our patients in the LAS group stayed in the hospital for
shorter times.
In another study, there was a trend toward more
postprocedural pulmonary complications in the GA group
(18).
Dall’Ara et al. could not show any difference in
complication rates such as myocardial infarction, major
stroke, and hospital deaths between the GA and LAS
groups (20). However, we had no such complications
during the procedure. We investigated 30-day mortality
in our patients, which gave similar results. In-hospital
mortality was comparable between the two groups in
another study also (18).
We performed GA for the first 79 patients in our
practice. Following this period, we had the LAS group.
There was a significant difference in anesthesia durations
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between GA and LAS groups (149 ± 48.7 min vs. 124.7
± 34.3 min, P < 0.001), although the procedure times
were comparable to each other (109.3 ± 46.6 min vs. 91.6
± 34.7 min). This could be the result of longer anesthetic
preparation time for GA than for LAS. The procedure time
in the GA group was also significantly longer than that of
the LAS group. This might be due to TEE usage, and also
more comfortable working conditions of the cardiologists.
Occasionally it has been reported that the anesthetic
drugs used in GA contribute to the depression of
cardiovascular function, leading to hemodynamic
instability requiring inotropic support (16). Additionally,
aortic stenosis patients cannot easily compensate for
hypotension and bradycardia. Guinot et al. had serious
hemodynamic instability required to be treated with two
concomitant vasoactive drugs in their patients undergoing
GA (9). However, this was just the opposite in the study of
Balanika et al., who reported a stable hemodynamic profile
in the patients undergoing GA (26). Thus, some authors
argue that more hemodynamic stability requiring less
inotropic support may be provided by sedation in awake
patients safely undergoing TAVI (24). This was confirmed
by another study as well (18). On the other hand, Dehedin
et al. found not only significantly less hemodynamic
instability and a shorter length of hospital stay in the
monitored anesthesia care (MAC) group compared to
the GA group, but also a significantly lower requirement
for vasoactive or inotropic drug use. The complication
incidence was higher in GA patients (27). These data were
comparable with Behan et al. and Motloch et al.’s findings,
but contrasted with a previous work by Bergmann et
al. that did not show any superiority of MAC over GA

management (28–30). Although length of stay in the
ICU and 30-day and 1-year mortality were comparable
between the groups, a high conversion rate (17%) from
GA to MAC was evaluated as a disadvantage of MAC
(20). Only two patients in this observation needed GA as a
result of lack of coordination with the anesthesiologist and
the procedure. It has been reported that almost 7%–20%
of patients under sedation required GA, with the urgent
management of intraoperative complications (27,29,30).
Unfortunately these were complications related to the
procedure; thus, it can be concluded that the procedure
itself, not the anesthesia technique chosen, determined
the prognosis (7). Although the patients were sedated
to be easily arousable, some patients had restlessness
and decreased oxygen saturations, although face mask
ventilation was applied. Thus, the anesthesia method was
changed to general anesthesia. These patients were elderly
and had compromised respiratory and cardiovascular
functions, such that drug eliminations and responses were
not always as we had imagined. As a result of this, keeping
airway safety was necessary in these patients.
We also had a high conversion rate from LAS to GA
of 16.7%, especially in those heavily sedated patients
experiencing hypercapnia, hypoxia, and hypotension.
In conclusion, we think that TAVI is emerging as a
safe and successful therapy in high-risk patients with
severe aortic stenosis in the case of no surgical options.
The anesthesiologist plays an essential role in the TAVI
team. For successful anesthetic management in these
patients, it is important to select the best approach with
the understanding of the patient’s health status and the
cardiac team and their choices.
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